Key points are not available for this paper at this time.
The CAZ-AVI + ATM combination offers a therapeutic advantage compared to OAAs for patients with BSI due to MBL-producing Enterobacterales. Further studies are warranted.
Falcone et al. (Tue,) studied this question.